Objective. To analyze factors influencing survival of patients with stage II colon cancer treated at our cancer center (Sparrow Hospital) from February 1996 through December 2006. Patients and methods. Survival analyses on 197 patients' age 71.1±0.9 years (29 to 97) were done using SAS system (V9.3, Cary NC). Analysis included age, gender, stage, surgery type, number of examined lymph nodes, pathological grade, tumor size and the use of adjuvant chemotherapy. Results. Mean follow up length was 48.1±2.3 months (0.1-133) and 56±3.3 (0.2-133) for survivors. The average number of removed lymph nodes was 18±13 (1-103). Adjuvant chemotherapy treatment (5-FU± leucovorin) was given to 49 patients, while others (148) were followed expectantly. There were 90 deaths during follow up. Only age exhibits a statistically significant relationship to survival (Hazard Ratio (HR) =1.06, 95% CI=1.03-1.08, p<0.001). Adjuvant chemotherapy possibly reduced the risk of death by 42% approaching a borderline advantage for survival (HR=0.58, CI=0.33-1.03, p=0.06. The number of removed lymph nodes also showed a possible relationship to survival (HR=0.98, CI= 0.62-1.56, p=0.07). Other investigated factors (gender, type of surgery, etc.) were not significant correlates. Conclusion. In this study we found that the most important factor for survival of patients with Stage II colon cancer is the patient's age. Adjuvant chemotherapy showed a borderline significance while the number of resected lymph nodes seemed to be an important survival factor. However, in our study statistical significance was not achieved.
Introduction
For more than 20 years, adjuvant chemotherapy has been shown to improve diseasefree survival (DFS) and overall survival (OS) in advanced colon cancer. Although it is agreed that patients with stage III disease benefit from adjuvant treatment, whether all patients with stage II disease should receive such treatment remains controversial.
At the center of this controversy are the contradictory conclusions derived by two large investigators' groups. The National Surgical Adjuvant Breast and Bowel Project (NSABP) concluded that the relative benefits of treatment were largely the same for stage II and stage III tumors (1) , whereas the International Multicenter Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) failed this as our oncologists also face a similar complex decision of treatment versus no treatment for stage II colon cancer patients and 3) finally we wanted to compare the survival of patients at our center to the national statistics for USA based on the factual information from our data outside the context of controlled clinical trials.
Patients and methods
We reviewed data of 197 patients who were examined, surgically treated and followed up by oncologists at Sparrow Hospital in Michigan for a ten-year time spanning from February 1996 through December 2006. The time to progression (TTP) was not calculated due to too few events observed in the follow up. Included in the analysis were: age, gender, stage (IIA vs. IIB), surgery type, number of examined lymph nodes, histological grade (well vs. moderately vs. poorly differentiated), tumor size and the use of adjuvant chemotherapy.
Statistical analysis
All data and survival analysis were performed using SAS statistical software (V9.3 (SAS Institute Inc., Cary, N.C.). Disease free survival (DFS) and Overall survival (OS) experience was characterized by constructing Kaplan-Meier survival curves. Cox proportional hazards models were used to assess differences in survival by baseline characteristics. For Disease free survival only cases with a notation of "Disease Free" were considered. This conservative approach was thought appropriate by the statistician as some cases marked as "Unknown" may well have been disease free. Subjects who died but whose deaths were determined to be unrelated to disease were censored at the time of last contact. A Type I error protection rate of 0.05 was assumed. All P values of less than .05 were considered statistically significant. to demonstrate a statistically significant benefit for stage II tumors (2, 3) .
FOLFOX has been approved in the adjuvant setting for stage III disease however the value of adjuvant therapy for stage II disease has been debated for decades. Recent data from large trials as well as pooled analyses seem to support its use (4) (5) (6) (7) (8) (9) (10) (11) . FU-based adjuvant chemotherapy in stage II patients is associated with a 2% to 4% benefit in 5-year DFS compared with surgery alone. On the basis of the MOSAIC results, adjuvant therapy for stage II patients with FOLFOX provides an improvement of 2.7% in 3-year DFS and 3.8% in 4-year DFS compared with optimized (infusional) FU/LV therapy (6, 7). If we postulate a 6% gain in 3-year DFS with FOLFOX in unselected stage II patients, this would translate an additional 1,250 patients free of disease every year in the United States (12) . In the US Surveillance, Epidemiology and End Results (SEER) Medicare population based study it was noted that treatment is being administered to a significant proportion of patients with low risk stage II colon cancer (13) .
For stage II colon cancer, several wellknown pathological and clinical factors are reported for instance: the age of the patient at diagnosis, tumor staging, number of involved lymph nodes, lymphovascular invasion, tumor grade and presence of bowel obstruction are associated with a higher risk of recurrence or death from the cancer. Identifying these factors is important to determine which patients may benefit the most from adjuvant therapy.
In the present study we sought to examine retrospectively the data of patients with Stage II colon cancer seen and treated at Sparrow Hospital from February 1996 through December 2006. There were 197 patients. Our aim was to 1) to find out if we can find an association of the reported factors with overall survival and disease free survival in our patients, 2) we sought to do
Ethics statement
This project was reviewed and was deemed as "an Exempt from IRB review status" by the Sparrow Institutional Research Review Committee (IRRC) according to the USA federal regulations. The confidentiality and the privacy of the subjects and the data were maintained as the data was obtained as anonymous from the tumor registry. No attempt was made to identify individuals. All authors have completed the Human subject Training required by the Sparrow IRRC and have adhered to ethical standards of Human subject research. (Figure 1) .
Results

Analysis was performed on 197 patients with
For progression free survival (disease free survival) only cases with a notation of "Disease Free" were considered to be free from progression. This is a conservative approach (but likely appropriate) as some cases marked as "Unknown" may well have been disease free. Subjects who died but whose deaths were determined to be unrelated to disease were censored at that point.
Overall survival (OS) for all patients was 90% at 12 months, 82% at 24 months and 56% at 60 months ( Figure 2) .
Patients more than 80 years old had 24 and 60 months survival of 66% and 33%, while at same time points, 92% and 78% of patients younger than 63 were still alive ( Figure 3 ) 
Discussion
The role of adjuvant chemotherapy in completely resected, pathological stage II colorectal cancer is an important unresolved area in the clinical care of the cancer patient. It warrants further investigation of survival factors in this population. Randomized controlled trials and meta-analyses have uniformly failed to definitively detect a survival benefit for adjuvant chemotherapy in stage II colon cancer. These trials have included insufficient numbers of patients with stage II disease to ultimately determine whether adjuvant chemotherapy in this population is truly beneficial. Nonetheless, there remains no clinical or biological reason to believe that the clinical behavior of stage II tumors should be different from that of stage III tumors. Analysis of pooled data from 4 NSABP studies and IMPACT B report raised more questions than answers about adjuvant chemotherapy in these patients (1-3). In the IMPACT B2 meta-analysis of stage II subgroups from five adjuvant trials, nonsignificant trends for improvements in DFS (73% vs. 76%) and OS (80% vs. 82%) were reported (4, 5) . A separate pooled-analysis of four consecutive NSABP adjuvant trials demonstrated consistent treatment benefits in both stage II and stage III patients, but interpretation was limited because of the heterogeneity of the treatments and control arms in the included trials (1). A differential magnitude of benefit was observed in a separate analysis done by Gill et al., with proportional reductions in risk of recurrence by 17% and death by 15% for nodenegative disease as compared with 40% and 35%, respectively, for node-positive disease (10) . A biologic explanation for a differential effectiveness of adjuvant FU-based therapy between node-negative and node-positive colon cancers has not been elucidated. It may be postulated that this effect is associated with Microsatellite instability (MSI), as a greater proportion of node-negative colon cancers observed have MSI-H phenotype (14) . Survival of 23,017 patients with Stage II colon cancer from American College of Surgeon Commission on Cancer (CoC) National Cancer Database (NCD) showed that 87.7% were alive at 12 months, 80.1% at 24 months and 61.4% at 60 months (15) . Data from this large database are very similar to the findings in our study with 90%, 82% and 56% survival at corresponding times. Observed 5-year survival rates for patients with stage II colon cancer from the same database diagnosed in 2000 were superior with adjuvant chemotherapy when compared to those who were observed (55.7% vs. 36.4%) (15) (16) . Although several statistically underpowered studies have not shown significant evidence of prolonged survival with adjuvant chemotherapy for patients with stage II colon cancer, a reduced risk of recurrence was seen retrospectively in the MOSAIC trial of adjuvant FOLFOX therapy for patients with high-risk stage II disease. Stage II colon cancer still presents a significant therapeutic challenge. Indeed, expert panels from both the National Cooperative Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) have recommended that adjuvant therapy for stage II disease be considered and discussed with patients. Both panels strongly recommended that such treatment be given within clinical trials, when possible. In view of all these controversies more data is needed for patients with stage 2 colon cancer within and outside clinical trials setting.
Despite the limitation of small sample size, our study also showed a tendency toward better survival in the chemotherapy treated group, but the results remained statistically insignificant (p=0.056). In a separate univariate analysis done by Gill et al. (10) , improvements with adjuvant chemotherapy did reach statistical significance for 5-year DFS (72% vs. 76%; p=0.0490), but did not for OS (80% vs. 81%; p=0.1127). Therefore, adjuvant chemotherapy in Stage II colon cancer still remains a viable option, but an OS benefit is not readily evident for all subgroups of patients.
Our study is based on the retrospective analysis of the data and as such it has limited power to predict prospective outcomes. It is also limited by the small sample size (197 patients) and the non-availability of all the literature reported risk factors. It is another, albeit small, contribution to the data examining the still unresolved question of the role of the adjuvant chemotherapy in the treatment of stage II colon cancer.
Our findings that age of the patients represents the most important prognostic survival factor in this disease are consistent with data from CoC NCD. There was evident difference in survival between age groups ( Figure 4 ) in this large national database. Patients 80-89 years of age had 5-year OS of 45%, while patients older than 90 were alive after 5 years in only 25% of cases. Patients younger than 60 years old had 5-year OS between 80% and 92%, with the very young group (30-39 years old) having excellent survival of 92%. These survival numbers are comparable with the data provided in our study (33% for patients older than 80 and 78% for patients younger than 63) confirming that patients treated in our hospital can expect survival similar to that achieved at national level. In our study data showed that patients were 5% more likely to die during the follow-up period for each year of age when entering study (with confidence interval between 3% and 7%).
Our study did not confirm potential survival impact of any other risk factors analyzed. In accordance with historical experience, size of the tumor did not impact survival, supporting practice not to include this factor into colon cancer staging schema. Number of evaluated lymph nodes was previously shown to be important prognostic factor in colon cancer (17) . Common explanation was that increased number of lymph nodes give us more reliable staging (Stage II vs. III). Herein we observed the same trend (border line statistical significance) in patients with single stage II colon cancer. Possible explanation for these findings is that elimination of larger number of lymph nodes reduces potentially residual burden of disease.
There is still controversy in the literature whether the number of lymph nodes resected and evaluated impacts patient outcomes (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . When lymph node (LN) number is used as categorical variable (> or < than 12 LN removed) was entered into the Cox model, results were consistent with those seen using LN count as a continuous variable (HR=0.98, CI=0.62-1.56, p=0.07). Therefore, our study does not support 12 LN benchmark. We recommend re-evaluation of this specific benchmark.
In our study there was no association between the survival and the sex of the patient. The stage of the disease 2A vs. 2B did not reach statistical significance, but both the widespread confidence interval (0.76-2.35) and the hazard ratio of 1.34 probably indicates that the sample size for analysis was too small and may be the stage of the tumor in itself is not a reliable parameter for the survival analysis.
We did not have available advanced genetic test results such as Microsatellite instability or Colo print (27) (28) (29) (30) (31) (32) . These tests identify important markers of tumor biology and can serve as drivers of treatment decisions. This represents another limitation of this study. More data is still needed to identify markers capable of establishing which stage 2 patients will suffer from recurrence and which could potentially benefit from adjuvant treatment.
Conclusion
Our study despite its limitations of retrospective data collection and the small number of patients did show that adjuvant chemotherapy could potentially be beneficial for the survival of patients with Stage II colon cancer. In addition, the number of resected lymph nodes (>12) seems to represent a distinct survival factor not only in Stage III, but also possibly in Stage II disease. However, the most important factor for survival is still age of the patient. Finally, survival of patients with Stage II colon cancer at Sparrow Hospital parallels national statistics for the United States of America.
